Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Assets (2016 - 2025)

Historic Assets for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $1.4 billion.

  • Ani Pharmaceuticals' Assets rose 938.15% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 938.15%. This contributed to the annual value of $1.3 billion for FY2024, which is 4193.56% up from last year.
  • Ani Pharmaceuticals' Assets amounted to $1.4 billion in Q3 2025, which was up 938.15% from $1.3 billion recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Assets high stood at $1.4 billion for Q3 2025, and its period low was $463.8 million during Q1 2021.
  • Over the past 5 years, Ani Pharmaceuticals' median Assets value was $859.3 million (recorded in 2023), while the average stood at $897.4 million.
  • Within the past 5 years, the most significant YoY rise in Ani Pharmaceuticals' Assets was 6730.59% (2021), while the steepest drop was 381.33% (2021).
  • Over the past 5 years, Ani Pharmaceuticals' Assets (Quarter) stood at $771.6 million in 2021, then decreased by 1.49% to $760.1 million in 2022, then rose by 18.99% to $904.4 million in 2023, then surged by 41.94% to $1.3 billion in 2024, then increased by 9.7% to $1.4 billion in 2025.
  • Its Assets stands at $1.4 billion for Q3 2025, versus $1.3 billion for Q2 2025 and $1.3 billion for Q1 2025.